AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.045

+0.0012.27%

Volume:778.41K

Turnover:35.67K

Market Cap:36.24M

PE:-5.13

High:0.048

Open:0.047

Low:0.045

Close:0.044

Loading ...

Overview Company News Filings

Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%

MT Newswires Live

BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug

BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation

Prescient Therapeutics Ltd - Ptx-100 Receives U.S. FDA Fast Track Designation

THOMSON REUTERS

Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%

MT Newswires Live

Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%

MT Newswires Live

Prescient Therapeutics Appoints Chair; Shares Fall 7%

MT Newswires Live

BRIEF-Prescient Therapeutics Says Steven Engle To Retire As Chair

Prescient Therapeutics Ltd - Steven Engle to Retire as Chair of Prescient Therapeutics on 30 March 2025

THOMSON REUTERS

Prescient Therapeutics Resumes OmniCAR Program After Developing New Variants

MT Newswires Live

BRIEF-Prescient Therapeutics Says OmniCAR Technical Issues Resolved

Prescient Therapeutics - Omnicar Technical Issues Resolved and Program to Progress

THOMSON REUTERS

Dusk Group Leads The Pack Of 3 ASX Penny Stocks

Simply Wall St.

Prescient Therapeutics Secures US FDA Clearance for Phase Two Lymphoma Trial; Shares Down 4%

MT Newswires Live

BRIEF-Prescient Therapeutics Appoints James Mcdonnell As Chief Executive Officer

Prescient Therapeutics Ltd - Appointment of James Mcdonnell as Chief Executive Officer

THOMSON REUTERS

ASX Penny Stocks: Prescient Therapeutics Among 3 Noteworthy Picks

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.045,"timestamp":1744870320000,"preClose":0.044,"halted":0,"volume":778405,"delay":0,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":662906718,"shares":805319793,"eps":-0.008776,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"04-17 16:12:00 AEST","open":0.047,"high":0.048,"low":0.045,"amount":35665,"amplitude":0.068182,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.008776,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.044,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.5115810855532027,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":662906718,"roa":"-17.58%","roe":"-36.95%","lyrEps":-0.010229,"volumeRatio":0.5115810855532027,"shares":805319793,"dividePrice":0,"high":0.048,"amplitude":0.068182,"preClose":0.044,"low":0.045,"week52Low":0.037,"pbRate":"2.32","psRate":"12.00","week52High":0.063,"institutionHeld":0,"latestPrice":0.045,"eps":-0.008776,"divideRate":0,"volume":778405,"delay":0,"ttmEps":-0.008776,"open":0.047,"prevYearClose":0.05,"prevWeekClose":0.045,"prevMonthClose":0.047,"prevQuarterClose":0.047,"fiveDayClose":0.041,"twentyDayClose":0.047,"sixtyDayClose":0.052},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528329537","title":"Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528329537","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528329537?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:18","pubTimestamp":1744863516,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  received a fast-track designation from the US Food and Drug Administration for its PTX-100 compound for the potential treatment of adults with relapsed or refractory mycosis fungoides, according to a Wednesday filing with the Australian bourse.The designation will expedite the review of therapies for serious conditions with high unmet need, enabling earlier delivery to patients, the filing said.Mycosis fungoides is a subtype of cutaneous T-cell lymphoma, a group of rare blood cancers affecting the skin.Shares rose nearly 5% in afternoon trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BYQQ9H92.USD","BK4139","FAST","LENZ","BK4585","BK7067","BK4007","IE00BFXG0V08.USD","BK4567","PTX.AU","IE00B5TLWC47.USD","BK4588","BK4104","BK7508"],"gpt_icon":0},{"id":"2527401260","title":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527401260","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527401260?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:35","pubTimestamp":1744767341,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug** Shares of Prescient Therapeutics PTX.AX rise as much as 28.6% to A$0.054, hit their highest levels since February 11** The clinical-stage oncology co says it received the US FDA Fast-Track designation for PTX-100, a treatment for adults with relapsed or refractory mycosis fungoides** PTX-100 is a compound with the ability to block an important cancer growth enzyme, says co** The fast-track status is an important step towards commercialisation of the drug, says co** About 2.7 million shares change hands, 4.3 times the 30-day average volume of shares** Stock down 16% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU034:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2527547722","title":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527547722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527547722?lang=en_us&edition=fundamental","pubTime":"2025-04-16 08:00","pubTimestamp":1744761636,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track DesignationApril 16 (Reuters) - Prescient Therapeutics Ltd PTX.AX:PTX-100 RECEIVES U.S. FDA FAST TRACK DESIGNATIONFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2527547420","title":"Prescient Therapeutics Ltd - Ptx-100 Receives U.S. FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527547420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527547420?lang=en_us&edition=fundamental","pubTime":"2025-04-16 07:20","pubTimestamp":1744759230,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT2HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522866954","title":"Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522866954","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522866954?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:52","pubTimestamp":1742957523,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK7508","BK4139","PTX.AU"],"gpt_icon":0},{"id":"2521731388","title":"Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521731388","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521731388?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:56","pubTimestamp":1742781393,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  appointed Marissa Lim as Chief Medical Officer, effective Monday, according to a same-day filing with the Australian bourse.Lim succeeds CMO Terrence Chew, who will continue with the company in an advisory capacity, per the filing.The clinical-stage oncology company's shares were down 4% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XAO.AU","XKO.AU","BK7508","XJO.AU","BK4139","LENZ","PTX.AU"],"gpt_icon":0},{"id":"2518736088","title":"Prescient Therapeutics Appoints Chair; Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518736088","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518736088?lang=en_us&edition=fundamental","pubTime":"2025-03-11 09:22","pubTimestamp":1741656156,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) appointed Non-Executive Director James Campbel as Chair, effective March 30, according to a Tuesday filing with the Australian bourse.Campbel will succeed former Chair Steven Engle, the filing said.Shares of the company fell past 7% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XJO.AU","XKO.AU","BK7067","XAO.AU","LENZ","BK4139","PTX.AU"],"gpt_icon":0},{"id":"2518705736","title":"BRIEF-Prescient Therapeutics Says Steven Engle To Retire As Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2518705736","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518705736?lang=en_us&edition=fundamental","pubTime":"2025-03-11 09:21","pubTimestamp":1741656090,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Says Steven Engle To Retire As ChairMarch 11 (Reuters) - Prescient Therapeutics Ltd PTX.AX:STEVEN ENGLE TO RETIRE AS CHAIR OF PRESCIENT THERAPEUTICS ON 30 MARCH 2025DR JAM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PT12F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2518784273","title":"Prescient Therapeutics Ltd - Steven Engle to Retire as Chair of Prescient Therapeutics on 30 March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518784273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518784273?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:52","pubTimestamp":1741647178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT12F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2505105107","title":"Prescient Therapeutics Resumes OmniCAR Program After Developing New Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2505105107","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505105107?lang=en_us&edition=fundamental","pubTime":"2025-01-23 15:02","pubTimestamp":1737615775,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  resolved the technical difficulties facing its OmniCAR program by creating a new generation of improved variants, according to a Thursday Australian bourse filing.OmniCAR is a CAR-cell platform, that enables controllable T-cell activity and multi-antigen targeting with a single-cell product.It observed that OmniCAR T-cells unarmed with antigen binders were demonstrating unexpected activity, which ran counter to \"the modular, controllable thesis\" of the program.It developed several OmniCAR variants over 2024 in collaboration with the Peter McCallum Cancer Center and Australia's Commonwealth Scientific and Industrial Research Organization, that overcame the issues observed with the previous OmniCAR version in preliminary in vitro and in vivo testing.When armed with binders, these new variants demonstrated highly effective tumor-killing activity in mice with Her2-positive tumors. The duration of efficacy was more than that of the previous version of the platform.It","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","XJO.AU","PTX.AU","XKO.AU","BK4139","XAO.AU","LENZ"],"gpt_icon":0},{"id":"2505082903","title":"BRIEF-Prescient Therapeutics Says OmniCAR Technical Issues Resolved","url":"https://stock-news.laohu8.com/highlight/detail?id=2505082903","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505082903?lang=en_us&edition=fundamental","pubTime":"2025-01-23 09:28","pubTimestamp":1737595700,"startTime":"0","endTime":"0","summary":"Jan 23 (Reuters) - Prescient Therapeutics Ltd   :   * OMNICAR TECHNICAL ISSUES RESOLVED AND PROGRAM TO PROGRESS Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2505707450","title":"Prescient Therapeutics - Omnicar Technical Issues Resolved and Program to Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2505707450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505707450?lang=en_us&edition=fundamental","pubTime":"2025-01-23 06:48","pubTimestamp":1737586089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI1AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2505796763","title":"Dusk Group Leads The Pack Of 3 ASX Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2505796763","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505796763?lang=en_us&edition=fundamental","pubTime":"2025-01-22 15:10","pubTimestamp":1737529853,"startTime":"0","endTime":"0","summary":"The Australian market has been buoyant, with the ASX200 reaching a seven-week high, driven by positive investor sentiment following Donald Trump's AI investment plan and favorable trade outcomes. In such an optimistic climate, investors often look beyond the major indices to explore opportunities in smaller companies that might offer both affordability and growth potential. Penny stocks, though a somewhat outdated term, still signify these smaller or emerging companies that can present significant value when backed by strong financials.Dusk Group, with a market cap of A$70.99 million, operates in the home fragrances sector, generating revenue of A$126.73 million. Despite having high-quality earnings and no debt concerns, Dusk's net profit margins have declined to 3.4% from 8.5% last year, and its earnings have decreased by an average of 9.5% annually over five years. The company is trading at a significant discount to its estimated fair value and shows potential for future growth with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dusk-group-leads-pack-3-071053032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PTX.AU","BK7077","XJO.AU","VLS.AU","IGL.AU","GTN.AU","XAO.AU","BK7045","BK7064","BK7070","BK7096","BK7132","BK7088","EVO.AU","HLO.AU","XKO.AU","BK7508","BK7067","STG.AU","BK7164","BK7133","BK7128","BK7055","SHA.AU","ANG.AU","SRV.AU","MXI.AU","DSK.AU","LBL.AU"],"gpt_icon":0},{"id":"2494481128","title":"Prescient Therapeutics Secures US FDA Clearance for Phase Two Lymphoma Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494481128","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494481128?lang=en_us&edition=fundamental","pubTime":"2024-12-27 09:19","pubTimestamp":1735262373,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  secured investigational new drug clearance from the US Food and Drug Administration to conduct a phase two trial of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas, according to a Monday filing with the Australian bourse.The two-part trial will investigate the optimal dose of PTX-100 and its efficacy, the filing said. It will be conducted across 15 global trial sites.The company's shares fell 4% in recent Friday trade.Price : $0.05, Change: $-0.002, Percent Change: -4.08%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTX.AU","LU0426412945.USD","LU0426417589.USD","BK7508","LU0345774631.USD","LU0994945656.USD","LENZ","LU2238339852.HKD","BK4125","LU1043141123.HKD","AUD","BK4139","BK7067"],"gpt_icon":0},{"id":"2492676443","title":"BRIEF-Prescient Therapeutics Appoints James Mcdonnell As Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492676443","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492676443?lang=en_us&edition=fundamental","pubTime":"2024-12-17 09:07","pubTimestamp":1734397620,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Prescient Therapeutics Ltd   :   * APPOINTMENT OF JAMES MCDONNELL AS CHIEF EXECUTIVE OFFICERFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2492167523","title":"Prescient Therapeutics Ltd -  Appointment of James Mcdonnell as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492167523","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492167523?lang=en_us&edition=fundamental","pubTime":"2024-12-17 08:52","pubTimestamp":1734396769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NH17K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2481194739","title":"ASX Penny Stocks: Prescient Therapeutics Among 3 Noteworthy Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2481194739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481194739?lang=en_us&edition=fundamental","pubTime":"2024-11-08 09:05","pubTimestamp":1731027900,"startTime":"0","endTime":"0","summary":"The Australian stock market is showing resilience, with the ASX200 rising by 0.80% and sectors like Materials and Real Estate leading the charge after recent volatility. In such a dynamic market landscape, investors often look for stocks that offer both value and growth potential, which can sometimes be found in smaller or newer companies. Though the term \"penny stocks\" might seem outdated, these investments can still provide significant opportunities when backed by solid financials; we'll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ptx/prescient-therapeutics-shares/news/asx-penny-stocks-prescient-therapeutics-among-3-noteworthy-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7132","BK7115","BK7062","BK7107","MXI.AU","PTX.AU","BK7502","XKO.AU","BK7067","BK7070","JYC.AU","BK7077","BRI.AU","EVO.AU","ANG.AU","BK7104","ATP.AU","PRN.AU","XJO.AU","BK7114","LENZ","BK7508","BK7131","VKA.AU","XAO.AU","QHL.AU","NGI.AU","BK7095","BK4139","LBL.AU","HLO.AU","BK7088"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[]}}